ATE269102T1 - Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums - Google Patents

Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums

Info

Publication number
ATE269102T1
ATE269102T1 AT95914690T AT95914690T ATE269102T1 AT E269102 T1 ATE269102 T1 AT E269102T1 AT 95914690 T AT95914690 T AT 95914690T AT 95914690 T AT95914690 T AT 95914690T AT E269102 T1 ATE269102 T1 AT E269102T1
Authority
AT
Austria
Prior art keywords
treatment
growth
stimulate bone
bone
growth factors
Prior art date
Application number
AT95914690T
Other languages
English (en)
Inventor
Colin R Dunstan
Elzbieta Izbicka
Gregory Mundy
Wilson Burgess
Michael C Jaye
Original Assignee
Osteosa Inc
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteosa Inc, Rhone Poulenc Rorer Pharma filed Critical Osteosa Inc
Application granted granted Critical
Publication of ATE269102T1 publication Critical patent/ATE269102T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C07K14/501—Fibroblast growth factors [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/85—Investigating moving fluids or granular solids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/02—Food
    • G01N33/10—Starch-containing substances, e.g. dough
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95914690T 1994-03-08 1995-03-06 Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums ATE269102T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20798594A 1994-03-08 1994-03-08
PCT/US1995/002847 WO1995024211A1 (en) 1994-03-08 1995-03-06 Use of fibroblast growth factors to stimulate bone growth

Publications (1)

Publication Number Publication Date
ATE269102T1 true ATE269102T1 (de) 2004-07-15

Family

ID=22772771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914690T ATE269102T1 (de) 1994-03-08 1995-03-06 Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums

Country Status (11)

Country Link
US (1) US5614496A (de)
EP (1) EP0881908B1 (de)
JP (1) JPH09510209A (de)
AT (1) ATE269102T1 (de)
AU (1) AU685619B2 (de)
CA (1) CA2184916C (de)
DE (1) DE69533176T2 (de)
DK (1) DK0881908T3 (de)
ES (1) ES2225840T3 (de)
PT (1) PT881908E (de)
WO (1) WO1995024211A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203913T1 (de) * 1993-05-31 2001-08-15 Kaken Pharma Co Ltd Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
US5656598A (en) * 1994-03-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Use of fibroblast growth factors to stimulate bone growth
EP0800530A4 (de) * 1994-07-20 1998-12-02 Celtrix Pharma Igf/igfbp-komplex zur förderung der knochenentwicklung und zur regulation des knochenumbaus
US6008208A (en) 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6221854B1 (en) * 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
DK1112095T3 (da) 1998-09-11 2003-03-17 Michael Dr Raschke Biologisk aktive implantater
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
EP1613267A2 (de) * 2003-03-27 2006-01-11 Children's Hospital Medical Center Verwendung von fgf- 18 protein, target-proteinen und ihren jeweiligen kodierenden nucleotid-sequenzen zur induktion von knorpelbildung
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
US20050244451A1 (en) * 2004-05-03 2005-11-03 Robert Diaz Method and device for reducing susceptibility to fractures in vertebral bodies
US20050244499A1 (en) * 2004-05-03 2005-11-03 Robert Diaz Method and device for reducing susceptibility to fractures in long bones
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US20060089642A1 (en) * 2004-10-27 2006-04-27 Diaz Robert L Prefracture spinal implant for osteoporotic unfractured bone
US7815926B2 (en) * 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
JP2009508596A (ja) 2005-09-19 2009-03-05 ヒストジェニックス コーポレイション 細胞支持基材及びその調製方法
US8298528B2 (en) * 2006-04-17 2012-10-30 Hepacore Ltd. Methods for bone regeneration using endothelial progenitor cell preparations
JP5815206B2 (ja) * 2006-08-25 2015-11-17 アレス トレーディング ソシエテ アノニム Ｆｇｆ−１８を用いた軟骨障害の治療
EP2083846B1 (de) 2006-09-28 2015-07-15 Hepacore Ltd. N-terminale fgf-varianten mit erhöhter rezeptor-selektivität und ihre verwendungen
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
WO2009111069A1 (en) 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
AU629316B2 (en) * 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
ATE139700T1 (de) * 1991-02-15 1996-07-15 Takeda Chemical Industries Ltd Mit einem zellwachstumsfaktor bewirkte anregung von wachstum im knocheninneren

Also Published As

Publication number Publication date
AU685619B2 (en) 1998-01-22
DE69533176T2 (de) 2005-09-15
WO1995024211A1 (en) 1995-09-14
EP0881908A4 (de) 2000-11-02
AU2157695A (en) 1995-09-25
US5614496A (en) 1997-03-25
PT881908E (pt) 2004-11-30
DK0881908T3 (da) 2004-10-25
CA2184916C (en) 2008-05-13
EP0881908A1 (de) 1998-12-09
CA2184916A1 (en) 1995-09-14
JPH09510209A (ja) 1997-10-14
ES2225840T3 (es) 2005-03-16
DE69533176D1 (de) 2004-07-22
EP0881908B1 (de) 2004-06-16

Similar Documents

Publication Publication Date Title
ATE269102T1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
ATE295734T1 (de) Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
RU2319483C2 (ru) Способ лечения и предупреждения потери костной ткани
DE69427947T2 (de) Verwendung von teilchen eines bioverträglichen und bioresorbierbaren kalziumsalzes als wirkstoff in der herstellung eines arzneimittels zur lokalen behandlung von entkalkungskrankheiten
DE69813908D1 (de) Verwendung von kreatinsubstanzen zur behandlung von knochen- und knorpelzellen und geweben
Mao et al. Strain induced osteogenesis of the craniofacial suture upon controlled delivery of low-frequency cyclic forces
NO924697D0 (no) Kirurgisk implantat og en fremgangsmaate for behandling avkirurgisk implantat
DE69631613D1 (de) Mit Verriegelungsmechanismus versehene Vorrichtung zur chirurgischen Behandlung von Gewebe
ATE255367T1 (de) Marknagelsystem zur frakturheilung bzw. knochenverlängerung
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ten Bruggenkate et al. Clinical evaluation of the ITI (F-type) hollow cylinder implant
MX9800801A (es) Proteina mp52 arg humana.
EP0585801A3 (en) Bone-related cadherin-like protein and process for its production
DE69133074D1 (de) Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten
KR950703993A (ko) 치주 조직 질환 치료제(periodonal disease remedy)
Stalnecker et al. Electrical stimulation of onlay bone grafts
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
SU1438725A1 (ru) Способ лечени ложных суставов
Friedlander et al. Selective resection of the circumoral musculature for enhancement of mandibular denture stability
TW224943B (en) The pharmaceutical composition for the stimulation of bone formation
SU1192799A1 (ru) Способ пластики крыши вертлужной впадины
MD899G2 (ro) Procedeu de activizare a osteogenezei reparatorii
Kentjono Rekonstruksi mandibula pasca reseksi tumor di Laboratorium Telinga Hidung dan Tenggorok RSU Dr. Soetomo Surabaya 1987-2003
UA33571A (uk) Спосіб лікування травматичного перелому нижньої щелепи
Held et al. The investigation period 1965–1970

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0881908

Country of ref document: EP